INTRODUCTION: Alzheimer's disease (AD) is an important public health problem due to its disabling character and high individual, familial and social costs. The CERAD neuropsychological battery has been widely used for evaluation and diagnosis of the cognitive deficit associated with AD. This instrument has been adapted to the Colombian culture (CERAD-Col) for the Neurosciences Group. SUBJECTS AND METHODS: A study was carried out to establish the validity and reliability of the CERAD-Col in Colombian, Spanish-speaking individuals aged 50 years or more. It included 151 controls and 151 AD patients. Controls were selected from a convenience sample of 848 adults aged 50 years or more. The construct validity was determined in three ways: 1) factorial analysis; 2) correlation with the functional scales FAST and GDS (convergent-type validity) and, 3) comparison between the two groups. Internal consistency was determined by means of Cronbach's alpha coefficient. RESULTS: Three factors -memory, language and praxis- explained 88% of the total variance. Moderate but statistically significant correlations were found between neuropsychological tests and functional scales. Internal consistency and test-retest reproducibility were high. The AD group exhibited significantly lower scores (p < 0.05) than the control one. CONCLUSION: CERAD-Col is valid and reliable for the diagnosis of AD in Colombian Spanish-speaking population aged 50 years or more.
INTRODUCTION:Alzheimer's disease (AD) is an important public health problem due to its disabling character and high individual, familial and social costs. The CERAD neuropsychological battery has been widely used for evaluation and diagnosis of the cognitive deficit associated with AD. This instrument has been adapted to the Colombian culture (CERAD-Col) for the Neurosciences Group. SUBJECTS AND METHODS: A study was carried out to establish the validity and reliability of the CERAD-Col in Colombian, Spanish-speaking individuals aged 50 years or more. It included 151 controls and 151 ADpatients. Controls were selected from a convenience sample of 848 adults aged 50 years or more. The construct validity was determined in three ways: 1) factorial analysis; 2) correlation with the functional scales FAST and GDS (convergent-type validity) and, 3) comparison between the two groups. Internal consistency was determined by means of Cronbach's alpha coefficient. RESULTS: Three factors -memory, language and praxis- explained 88% of the total variance. Moderate but statistically significant correlations were found between neuropsychological tests and functional scales. Internal consistency and test-retest reproducibility were high. The AD group exhibited significantly lower scores (p < 0.05) than the control one. CONCLUSION: CERAD-Col is valid and reliable for the diagnosis of AD in Colombian Spanish-speaking population aged 50 years or more.
Authors: Yakeel T Quiroz; Andrew E Budson; Kim Celone; Adriana Ruiz; Randall Newmark; Gabriel Castrillón; Francisco Lopera; Chantal E Stern Journal: Ann Neurol Date: 2010-12 Impact factor: 10.422
Authors: José R Carrión-Baralt; Josefina Meléndez-Cabrero; Michal Schnaider Beeri; Mary Sano; Jeremy M Silverman Journal: Dement Geriatr Cogn Disord Date: 2009-03-17 Impact factor: 2.959
Authors: Yakeel T Quiroz; Henrik Zetterberg; Eric M Reiman; Yinghua Chen; Yi Su; Joshua T Fox-Fuller; Gloria Garcia; Andres Villegas; Diego Sepulveda-Falla; Marina Villada; Joseph F Arboleda-Velasquez; Edmarie Guzmán-Vélez; Clara Vila-Castelar; Brian A Gordon; Stephanie A Schultz; Hillary D Protas; Valentina Ghisays; Margarita Giraldo; Victoria Tirado; Ana Baena; Claudia Munoz; Silvia Rios-Romenets; Pierre N Tariot; Kaj Blennow; Francisco Lopera Journal: Lancet Neurol Date: 2020-05-26 Impact factor: 44.182
Authors: Laura Ramirez Aguilar; Juliana Acosta-Uribe; Margarita M Giraldo; Sonia Moreno; Ana Baena; Diana Alzate; Rosario Cuastumal; David Aguillón; Lucía Madrigal; Amanda Saldarriaga; Alexander Navarro; Gloria P Garcia; Daniel C Aguirre-Acevedo; Ethan G Geier; J Nicholas Cochran; Yakeel T Quiroz; Richard M Myers; Jennifer S Yokoyama; Kenneth S Kosik; Francisco Lopera Journal: Alzheimers Dement Date: 2019-02-10 Impact factor: 21.566
Authors: Daniel C Aguirre-Acevedo; Francisco Lopera; Eliana Henao; Victoria Tirado; Claudia Muñoz; Margarita Giraldo; Shrikant I Bangdiwala; Eric M Reiman; Pierre N Tariot; Jessica B Langbaum; Yakeel T Quiroz; Fabian Jaimes Journal: JAMA Neurol Date: 2016-04 Impact factor: 18.302
Authors: Yakeel T Quiroz; Reisa A Sperling; Daniel J Norton; Ana Baena; Joseph F Arboleda-Velasquez; Danielle Cosio; Aaron Schultz; Molly Lapoint; Edmarie Guzman-Velez; John B Miller; Leo A Kim; Kewei Chen; Pierre N Tariot; Francisco Lopera; Eric M Reiman; Keith A Johnson Journal: JAMA Neurol Date: 2018-05-01 Impact factor: 18.302
Authors: Y T Quiroz; B A Ally; K Celone; J McKeever; A L Ruiz-Rizzo; F Lopera; C E Stern; A E Budson Journal: Neurology Date: 2011-07-20 Impact factor: 9.910
Authors: Yakeel T Quiroz; Kim Celone Willment; Gabriel Castrillon; Martha Muniz; Francisco Lopera; Andrew Budson; Chantal E Stern Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Edmarie Guzmán-Vélez; Sehily Jaimes; Daniel C Aguirre-Acevedo; Daniel J Norton; Kathryn V Papp; Rebecca Amariglio; Dorene Rentz; Ana Baena; Eliana Henao; Victoria Tirado; Claudia Muñoz; Margarita Giraldo; Reisa A Sperling; Francisco Lopera; Yakeel T Quiroz Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472